yahoo. Phase 1 clinical trial dosing completed Phase 1b/2a clinical trial of NVG-291 in individuals with chronic and subacute spinal cord injuries expected to commence in Q3 2023 Cash and investments of $18. 064 USD Historical index on US Stock Market : A "Should I invest in NervGen Pharma stock?" "Should I trade "NGENF" stock today?" According to our live Forecast System,. Mkt Cap: US$90. 9800 +0. Daniel Mikol, will present at the 2023 International Spinal Research Trust Network Meeting being held September 14-16 in London, UK. 806 CAD. OTCPK:NGEN. Find NervGen Pharma Smart Score, expert sentiment, charts & stats. NervGen Pharma's estimated fair value is CA$3. Their latest funding was raised on Oct 12, 2022 from a Grant round. 2%. - June 2, 2023) - NervGen Pharma Corp. - October 27, 2021) - NervGen Pharma Corp. Market Average Movement. Find NervGen Pharma Smart Score, expert sentiment, charts & stats. The decrease was primarily due to non-cash stock-based compensation expense related to option grants to employees and consultants, and the timing of the related vesting, partially offset by increases in legal, professional, and. Nervgen Pharma Corp stocks price quote with latest real-time prices, charts, financials, latest news, technical analysis and opinions. Cash Markets Overview Corn Indexes Soybean Indexes Wheat Indexes Energies Indexes Yield Forecast Indexes. 8 million as of September 30, 2023, compared to $22. 12,500. Get the latest NervGen Pharma Corp (NGENF) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions. Nervgen Pharma Corp. - August 22, 2023) - NervGen Pharma Corp. 532. It is currently in Phase 1 FDA trials in humans and is about to go into Phase 2. 52%) At close: 03:59PM EST 1d 5d 1m 6m YTD 1y 5y Max Full. The net cash burn for Q1 2021 from operating. Cash and Investments: NervGen had cash and investments of $18. 22%. 0 million as of March 31, 2023, compared to $22. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system. Receives Up to $1. NervGen (TSX-V: NGEN, OTCQX: NGENF) is a clinical stage biotech company dedicated to developing innovative treatments that enable the nervous system to repair itself. Discover NervGen Pharma's earnings and revenue growth rates, forecasts, and the latest analyst predictions while comparing them to its industry peers. ISIN. - April 10, 2023) - NervGen Pharma Corp. Bill Radvak, Co-founder and Executive Chairman of the Board, appointed interim Chief. 17. VANCOUVER, BC — Newsfile Corp. 'NervGen made. February 23, 2023 – NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, announced today that President & CEO, Mike Kelly, will present at the H. October 27, 2021 - NervGen Pharma Corp. Vancouver, Canada. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical stage biotech company dedicated to. Projected one-year return to target: 168 per cent. NervGen Pharma press release (OTCQX:NGENF): Q3 GAAP EPS of -$0. Vancouver, British Columbia--(Newsfile Corp. Fair Ratio; Current PB Ratio: 15. Vancouver, British Columbia--(Newsfile Corp. stock price gained 0. Nervgen Pharma Corp is in the bottom half of stocks based on the fundamental outlook for the stock and an analysis of the stock's chart. NervGen Pharma Corp. For NervGen Pharma, we've compiled three additional factors you should further research: Risks : Be aware that NervGen Pharma is showing 5 warning signs in our investment analysis , and 3 of those. Vancouver, Canada. $34. 49% from the latest price. 50 per unit, for aggregate gross proceeds of. Corporate Communications (604) 537-2094. 09% 5 days −5. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023. NervGen Pharma has received approval to enroll a third and final group of healthy volunteers in the multiple ascending dose (MAD) segment of its Phase 1 clinical trial of NVG-291, an. NervGen has exclusive rights to the technology from Case Western University. Vancouver, British Columbia-- (Newsfile Corp. Anthera Pharmaceuticals's stock reverse split on the morning of Monday, May 1st 2017. April 10, 2023 – NervGen Pharma Corp. 5 million as of December 31, 2022. 1. NervGen Pharma press release (NGENF): Q2 GAAP EPS of -$0. All options. Vancouver, British Columbia-- (Newsfile Corp. Currency in CAD. 5 million as of December 31, 2022. Stock Price & Overview 433 followers $1. Vancouver, Canada. Food and. 1. May 6, 2021 – NervGen Pharma Corp. NervGen Pharma (NGEN) financials statements overview reports - NervGen Pharma's market cap is currently ―. Phase 1a/2b clinical trial of NVG-291 underway with dosing of individuals with spinal cord injury; results from chronic. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" the "Company"), a clinical. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, announced that all subjects (male, premenopausal. 2. (TSX-V: NGEN;. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. The company’s lead target. See the latest NervGen Pharma Corp Ordinary Shares stock price (NGENF:PINX),. Daniel Mikol, will present at the 2023 International Spinal. 3 Bil: BMRN Biomarin Pharmaceutical Inc: Jdmlf: $15. NGENF chart. It is backed by top experts in the field and staffed by very high-level pharma executives. 28 +1. (NGEN) stock price, news, historical charts, analyst ratings and financial information from WSJ. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES Vancouver, Canada. February 24, 2020 – NervGen Pharma Corp. Vancouver, British Columbia--(Newsfile Corp. August 10, 2022 – NervGen Pharma Corp. See the latest NervGen Pharma Corp Ordinary Shares stock price (NGENF:PINX),. The stock at $80 million mkt cap can 10 to 100 bag as. Nancy ThompsonOffice (212) 532-2208Mobile (917) 371-4053Just because a business does not make any money, does not mean that the stock will go down. 6 million in proceeds from the exercise of. NervGen’s lead drug candidate, NVG-291, is being evaluated in a Phase 1b/2a clinical trial. 87%. Vancouver, British Columbia--(Newsfile Corp. Discover historical prices for NGEN. The stock has stayed mostly between $1 and $3 over that time period, with. 0 Bil: INCY NGENF Nervgen Consolidation continues Possible entry ahead Nice long ~2 year consolidation is in progress, recent reject from the top side of wedge will present entry opportunities Entry target ~ 1. Find the latest NervGen Pharma Corp. 2208 Follow NervGen on Twitter, LinkedIn, and Facebook. 0800 (+4. Operational highlights. NervGen Pharma Corp. Bill Radvak is a co-founder and has been the Executive Chairman or Chairman of NervGen since its inception. CI. Forecast Changes; Commodities. $ 1. NervGen Pharma Corp. Cash and Investments: NervGen had cash and investments of $16. Newsfile Corp. to open at $1. (TSX-V: NGEN; OTCQX: NGENF). (TSXV: NGEN) (OTCQX: NGENF) (" NervGen " or the " Company "), a clinical stage biotech company dedicated to creating innovative treatments for nervous system damage, is pleased to announce the closing of its previously announced public. under the Business Corporations Act (British Columbia). stock indexes jumped more than 1% Tuesday morning, with the coming close to a 2% gain. (TSXV: NGEN) (OTCQX: NGENF) (" NervGen " or the " Company "), a clinical stage biotech company dedicated to creating innovative treatments for nervous system damage, is pleased to announce the closing of its previously announced public. yahoo. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, announced a two-year extension of the expiry date. Top Smart Score Stocks. 3. - November 8, 2023) - NervGen Pharma Corp. Vancouver, British Columbia--(Newsfile Corp. May 12, 2022 – NervGen Pharma Corp. Vancouver, Canada August 2, 2022 – NervGen Pharma Corp. About NervGen. Vancouver, British. VIX Bitcoin Crude Oil Dollar Index Future Index Barron's 400 Market Data Stocks NGENF Overview NervGen Pharma Corp. NervGen (TSX-V: NGEN, OTCQX: NGENF) is a clinical stage biotech company dedicated to developing innovative treatments that enable the nervous system to repair itself following damage, whether due to injury or disease. 950 CAD. August 4, 2020 — NervGen Pharma Corp. (the "Company" or "NervGen") and should be read in conjunction with the accompanying consolidated financial statements and related notes thereto for the period ended September 30, 2021. (TSX-V: NGEN) (OTCQX: NGENF) (“NervGen” or the “Company”), a clinical stage biotech company dedicated to developing innovative treatments for nerve damage and neurodegenerative diseases, is pleased to announce today that the first subject has been dosed with NVG-291 in the. Vancouver - NervGen Pharma Corp. NervGen Pharma Corp. NervGen Pharma Reports Q3 2023 Financial Results and Operational Updates. Receives FDA Authorization to Expand Enrollment of Males and Premenopausal Females in Phase 1 Clinical Trial of NervGen's NVG-291 2022Cash and Investments: NervGen had cash and investments of $5. 5d. Kelly exercisable at a price of $1. All options, which will vest over two years, have been granted in accordance with the policies of the TSX Venture Exchange and the Company’s. (TSXV: NGEN) (OTCQX: NGENF), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, has received Institutional Review Board (IRB) approval for its landmark Phase 1b/2a proof-of-concept clinical trial protocol of its proprietary lead compound, NVG. During the 2022 fiscal year and 2023 to date, we have received proceeds of approximately CA$3. (TSX-V: NGEN) (OTCQX: NGENF) (“NervGen” or the “Company”), a regenerative medicine company dedicated to creating innovative solutions for the treatment of nerve damage and neurodegenerative diseases, today announced the Company has agreed to amend the. 5 million as of December 31, 2022As at September 30, 2023, we have achieved three of the five milestones in the grant, and received US$1. The stock could jump quickly if the Company receives EU. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a. Vancouver, British Columbia-- (Newsfile Corp. 1. NervGen Pharma Stock Forecast, NGEN stock price prediction. 5 million as of December 31, 2022. NervGen’s lead drug candidate, NVG-291, is being evaluated in a Phase 1b/2a clinical trial. The company’s lead target. Description. Cash and investments of $18. - November 8, 2023) - NervGen Pharma Corp. Research NervGen Pharma's (TSXV:NGEN) stock key valuation metrics while comparing it with its industry peers & market side by side. 4 per cent over the last 12 months, though investors who bought in to start 2022 have seen a 24. (the “Company” or “NervGen”) is a publicly traded company incorporated on January 19, 2017, under the Business Corporations Act (British Columbia). (TSX-V: NGEN; OTCQX: NGENF) (“NervGen” the “Company”), a clinical stage biotech company dedicated to developing a first-in-class neuroreparative drug to treat nervous system damage, announced that it has closed its previously announced non-brokered private placement. The company’s lead target. Latest Financial Results Quarter Ended September 30, 2023 Financial Statements MD&A Past Financial Results 2023 Quarter Ended June 30, 2023 Financial Statements MD&A Quarter Ended March 31, 2023 Financial Statements MD&A 2022 Year Ended December 31, 2022 Quarter Ended September 30, 2022 Quarter Ended June 30,. 0164 / +1. Please note that any opinions, estimates or forecasts regarding NervGen Pharma Corp. Vancouver - NervGen Pharma Corp. Since then, NGENF stock has increased by 19. 81(+0. September 5, 2023 – NervGen Pharma Corp. (TSX-V: NGEN; OTCQX: NGENF) (“NervGen” or the “Company”), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, today reported its financial and operational results for the year ended December 31, 2021. According to present data NervGen Pharma's NGENF shares and potentially its market environment have been in a bullish cycle in the last 12 months (if exists). 6 million as of December 31, 2020. 5 million as of December 31, 2022. This was offset by approximately $0. Read the press release to learn more about this breakthrough therapy and the ongoing clinical trial. 0 million as of March 31, 2023 Vancouver, Canada. 8 million as of September 30, 2023, compared to $22. 32; its P/E ratio is -5. Radvak has been the chief executive officer and director of multiple start-up companies. Share your opinion and gain insight from other stock traders and investors. According to present data NervGen Pharma's NGEN shares and potentially its market environment have been in bearish cycle last 12 months (if exists). (TSXV: NGEN). V) TSXV - TSXV Real Time Price. (TSX-V: NGEN) (OTCQX: NGENF) ('NervGen' or the 'Company'), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, will be giving an oral presentation at the upcoming American Spinal Injury Association (ASIA) 50th Annual. NervGen (TSX-V: NGEN, OTCQX: NGENF) is a clinical stage biotech company dedicated to developing innovative treatments that enable the nervous system to repair itself following damage, whether due to injury or disease. Announces Executive Changes 2022: CI NervGen Pharma Corp. NervGen plans to initiate. Russell 2000 Futures 1,736. NGENF shares are trading down $0. 0015 (+0. . , a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, today reported its financial and operational results. S. , a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, today announced the appointment of John Ruffolo. Mr. Vancouver - NervGen Pharma Corp. , has announced its successful completion of dosing of all. Vancouver, British Columbia-- (Newsfile Corp. announced that the Company has granted 285,000 incentive stock options to directors of the Company and 10,000 incentive stock options to. If these results can be transferred to humans, it would be a milestone for many currently incurable diseases. 97 NGEN 0. Company Overview; 1 Valuation;. NervGen (TSX-V: NGEN, OTCQX: NGENF) is a clinical stage biotech company dedicated to developing innovative treatments that enable the nervous system to repair itself following damage, whether due to injury or disease. Stock-based compensation 4,015,673 3,415,360 Unrealized foreign exchange (31,377) 16,610 Changes in non-cash working capital: Accounts receivable (1,408) 59,908. The Company has granted 800,000 incentive stock options exercisable at a price of $3. View Release. 0 million as of March 31, 2023. NervGen Pharma General Information. Mr. 39 to $1. NervGen Pharma Corp. Stock-based compensation - - 775,997 - 775,997 Loss and comprehensive loss - - - (2,247,417) (2,247,417). The decrease was primarily due to non-cash stock-based compensation expense related to option grants to employees and consultants, and the timing of the related vesting, partially offset by increases in legal, professional, and. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical stage biotech company dedicated to. 1. (TSX-V: NGEN) (OTCQX: NGENF), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, announces the results of its Annual General. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI Oct. (TSXV: NGEN) (OTCQX: NGENF), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, announced today that renowned neuroscientist, Dr. 36. 92% from the latest price. 09. NervGen Pharma stock price as been showing a rising tendency so we believe that similar market segments. Cash and Investments: NervGen had cash and investments of $11. (TSX-V: NGEN;. Stock-based compensation - - 775,997 - 775,997 Loss and comprehensive loss - - - (2,247,417) (2,247,417). Phase 1a/2b clinical trial of NVG-291 underway with dosing of individuals with spinal cord injury; results from chronic. Vancouver, British Columbia--(Newsfile Corp. - December 15, 2020) - NervGen Pharma Corp. Popular. 5 Million US Department of Defense Funding to Evaluate NervGen's NVG-291-R for Peripheral Nerve InjuryNervGen Pharma Corp. Overall, NervGen Pharma’s stock price has risen by 6. Vancouver - NervGen Pharma Corp. Browse analyst ratings and price targets on all stocks. 80 -3. View the latest NervGen Pharma Corp. +21. NervGen had cash and investments of $14. (NGEN. Vancouver, British Columbia--(Newsfile Corp. 07. The options have been granted in accordance with the. Wainwright 25th Annual Global Investment Conference. (212) 532-2208. Injury can occur at any level of the spinal cord and can. (NGEN:CA) stock. Read More ». NervGen Pharma Corp. 15-1. NervGen Pharma Receives Fast Track Designation for NVG-291 for the Treatment of Individuals with Spinal Cord Injury. 1. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" the "Company"), a clinical stage biotech company dedicated to developing a first-in-class neuroreparative drug to treat nervous system damage, announced that it has closed its previously announced non. 005 USD for 2028 November 11, Saturday with technical analysis. Financial Highlights. NervGen's lead drug candidate, NVG-291, is currently planned to be evaluated in a Phase 1b/2a clinical trial. 477967017318 USD for 2024 November 11, Monday; and 9. 77% 5 years 11. About NervGen. , a (formerly publicly listed) medical device company (which continues to carry on that. View real-time stock prices and stock quotes for a full financial overview. Vancouver, British Columbia-- (Newsfile Corp. 0164. (TSX-V: NGEN) (OTCQX: NGENF) (“NervGen” or. Receives Fast Track Designation for NVG-291 for the Treatment of Individuals with Spinal Cord Injury CINervGen Pharma (NervGen Pharma Stock Quote, Charts, News, Analysts, Financials TSXV:NGEN) Rating: Speculative Buy Target Price: $6. (TSX-V: NGEN) (OTCQX: NGENF) ('NervGen' or the 'Company'), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, will be giving an oral presentation at the upcoming American Spinal Injury Association (ASIA) 50th Annual Scientific Meeting being held on April 17-19, 2023. July 5, 2019 – NervGen Pharma Corp. (TSX-V: NGEN) (OTCQX: NGENF) (“NervGen” or the “Company”), a regenerative medicine company dedicated to creating innovative solutions for the treatment of nerve damage, today announced that it has entered into an agreement to issue 1,500,000 common shares at a. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, announced today that it has been awarded a grant. Vancouver, Canada. NervGen’s lead drug candidate, NVG-291, is currently in a Phase 1 clinical trial. 2021 ANNUAL FINANCIAL STATEMENTS 5 1. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES Vancouver, Canada November 12, 2021 – NervGen Pharma Corp. 3 million in proceeds from the exercise of options and warrants during the. For more information. NervGen (TSX-V: NGEN, OTCQX: NGENF) is a clinical stage biotech company dedicated to developing innovative treatments that enable the nervous system to repair itself following damage, whether due to injury or disease. Oct. (NGENF) stocks, the next step is researching the company. Currency in CAD. 1. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later. 295$ and our data indicates that the asset price has been in an uptrend for the past 1 year (or since its inception). - August 8, 2023) - NervGen Pharma Corp. View the. NervGen Pharma (NGENF) has announced the appointment of Mr. 2023-04-10 09:44 ET - News Release. (TSXV: NGEN) (OTCQX: NGENF), a clinical stage biotech company dedicated to developing innovative solutions. stock information by Barron's. We continued to advance our Phase 1. Financial Highlights. NOT FOR DISTRIBUTION TO U. NervGen Pharma Corp (NGENF) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets. NervGen Pharma to Present on its Drug Candidate NVG-291 and Spinal Cord Injury at Investor Conference. June 27, 2023 – NervGen Pharma Corp. The net cash burn for Q3 2023 from operating and investing activities was approximately $1. (TSX-V: NGEN; OTCQX: NGENF) (“NervGen” or the “Company”), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, announced that the Company has granted 285,000 incentive stock options to directors of the. (TSXV: NGEN) (OTCQX: NGENF), a clinical stage biotech company dedicated to developing innovative. Today’s Change. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a. Stock-based compensation - - 797,101 - 797,101 . Currency in USD Follow 1. For example, although. In addition, Cloutier Consulting was granted 52,500 incentive stock options on October 28, 2022, exercisable at a price of $1. NERVGEN PHARMA CORP. In July 2022, NervGen Pharma announced the University of Cincinnati and Case Western Reserve University (CWRU) had published a pioneering preclinical study in the peer-reviewed scientific journal. This was offset by approximately $0. Receives Up to $1. For instance, just consider the fact that Wall Street analysts are now estimating peak annual sales for Biogen’s new drug will range from $10 billion to $50 billion. May 15, 2023 – NervGen Pharma Corp. Nervgen Pharma Corp is in the bottom half of stocks based on the fundamental outlook for the stock and an analysis of the stock's chart. Vancouver, British Columbia--(Newsfile Corp. announced the appointment of Mr. Nature of business . NervGen Pharma Corp. V) stock news and headlines to help you in your trading and investing decisions. NervGen (TSX-V: NGEN, OTCQX: NGENF) is a clinical stage biotech company dedicated to developing innovative treatments that enable the nervous system to repair itself following damage, whether due to injury or disease. +16. Chronic spinal cord injury cohort results expected in mid-2024 Subacute spinal cord injury cohort results expected in late 2024/early 2025Vancouver, British Columbia--(Newsfile Corp. Price target in 14 days: 1. NERVGEN PHARMA CORP. 88, which is an increase of 123. Vancouver, British Columbia-- (Newsfile Corp. VANCOUVER, British Columbia--(BUSINESS WIRE)-- NervGen Pharma Corp. Vancouver, British Columbia--(Newsfile Corp. VANCOUVER, BC — Newsfile Corp. 0 Bil: INCYView live NervGen Pharma Corp. Vancouver, Canada. - May 15, 2023) - NervGen Pharma Corp. (the “Company” or “NervGen”) is a publicly traded company incorporated on January 19, 2017 under the Business Corporations Act (British Columbia). was tempered with the announcement of a slow growth forecast ahead. com 604. com. 6 million. Jerry Silver, inventor of NervGen's. 80(-0. It does not constitute a recommendation. S. NervGen Pharma Corp. V) TSXV - TSXV Real Time Price. Food and Drug Administration (FDA) has. Nov. He was a founder and the CEO of Response Biomedical Corp. F Stock Report. News and Insights->->Vancouver, Canada. NervGen Pharma Corp. The Company's initial target indication is spinal cord injury. 65%) Gold 1,969. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical stage biotech company dedicated to. NervGen Pharma Corp. 89%. finance. 30/share on May 31, but not quite reaching the high. NGENF shares are trading down $0. - NervGen Pharma Corp. - April 10, 2023) - NervGen Pharma Corp. 42. S. | 1,176 followers on LinkedIn. Vancouver, British Columbia–(Newsfile Corp. Inquiries. Please note that any opinions, estimates or forecasts regarding NervGen Pharma Corp. 48 +11. 3% and is now trading at $1. Expands research capabilities aiming to build pipeline of proprietary compounds for nervous system repair Lukashev brings over 20 years’ experience including work at Biogen and the ALS Therapy Development Institute Vancouver, Canada. Vancouver, British Columbia-- (Newsfile Corp. Volatility Over Time: NGEN's weekly volatility (7%) has been stable. Current Price 1. NervGen (TSX-V: NGEN, OTCQX: NGENF) is a clinical stage biotech company dedicated to developing innovative treatments that enable the nervous system to repair itself following damage, whether due to injury or disease. The following discussion is management's assessment and analysis of the results of operations and financial conditions of NervGen Pharma Corp. (NGENF) Other OTC - Other OTC Delayed Price. 23. Vancouver, British Columbia--(Newsfile Corp. (TSXV: NGEN) (OTCQX: NGENF), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, announced today that renowned neuroscientist, Dr. - October 17, 2023) - NervGen Pharma Corp. " The 12-month stock price forecast is $21. (NGEN. The Company has also granted 2,892,000 incentive stock options to Mr. S. Get the latest NervGen Pharma Corp (NGEN) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions. (TSX-V: NGEN; OTCQX: NGENF) ('NervGen' or the 'Company'), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, today reported its financial results for the third quarter ended September 30, 2022 and provided an operational update. An investor that had 100 shares of stock prior to the reverse split would have 13 shares. 0164 / +1. ( CVE:NGEN ) by taking the. — NervGen Pharma Corp. 30/share on May 31, but not quite reaching the high. - May 18, 2023) - NervGen Pharma Corp. 1. S. - June 2, 2023) - NervGen Pharma Corp. Multiple Sclerosis Facts and Figures In the U. Vancouver, Canada. (NGENF) stock quote, history, news and other vital information to. 19 at the beginning of 2023.